EUVIMEDEUVIMED entdecken
Open Access

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

Tom G Caniels iD, Max Medina-Ramìrez iD, Shiyu Zhang iD, Sven Kratochvil iD, Yuejiao Xian, Ja-Hyun Koo iD, Ronald Derking, Jakob Samsel iD, Jelle van Schooten iD, Simone Pecetta iD, Edward Lamperti iD, Meng Yuan iD und 36 weitere

Science Immunology · 30.08.2024 · 9 (98)

DOI: 10.1126/sciimmunol.adk9550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 30.08.2024. Verfasst von Tom G Caniels und 47 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, location AMC, University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Amsterdam, Netherlands. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Antibodies, Antibodies, Neutralizing, HIV-1. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gates Foundation, NIGMS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine development. Here, we describe how germline-targeting immunogen BG505 SOSIP germline trimer 1.1 (GT1.1), generated through structure-based design, engages a diverse range of VRC01-class bnAb precursors. A single immunization with GT1.1 expands CD4 binding site (CD4bs)–specific VRC01-class B cells in knock-in mice and drives VRC01-class maturation. In nonhuman primates (NHPs), GT1.1 primes CD4bs-specific neutralizing serum responses. Selected monoclonal antibodies (mAbs) isolated from GT1.1-immunized NHPs neutralize fully glycosylated BG505 virus. Two mAbs, 12C11 and 21N13, neutralize subsets of diverse heterologous neutralization-resistant viruses. High-resolution structures revealed that 21N13 targets the same conserved residues in the CD4bs as VRC01-class and CH235-class bnAbs despite its low sequence similarity (~40%), whereas mAb 12C11 binds predominantly through its heavy chain complementarity-determining region 3. These preclinical data underpin the ongoing evaluation of GT1.1 in a phase 1 clinical trial in healthy volunteers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesHIV AntibodiesAntibodies, NeutralizingHIV-1CD4 AntigensAnimalsMiceHumansBinding SitesHIV InfectionsVaccinationAntibodies, MonoclonalFemale

Substanzen

AIDS VaccinesHIV AntibodiesAntibodies, NeutralizingCD4 AntigensAntibodies, Monoclonal

Autor:innen und Institutionen

  • Amsterdam UMC, location AMC, University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Amsterdam, Netherlands.
  • Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.
  • Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.
  • Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA.
  • Vaccine Research Center (VRC), NIAID, NIH, Bethesda, MD, USA.
  • Institute for Biomedical Sciences, George Washington University, Washington, DC, USA.

ORCID-Profile: Tom G Caniels, Max Medina-Ramìrez, Shiyu Zhang, Sven Kratochvil, Ja-Hyun Koo, Jakob Samsel, Jelle van Schooten, Simone Pecetta, Edward Lamperti, Meng Yuan, María Ríos Carrasco, Iván Del Moral Sánchez, Joel D Allen, Joey H Bouhuijs, Anila Yasmeen, Thomas J Ketas, Jonne L Snitselaar, Isabel Cuella Martin, Jonathan L Torres, Albert Cupo, Lisa Shirreff, Kenneth Rogers, Rosemarie D Mason, Mario Roederer, Hongmei Gao, Catarina Mendes Silva, Isabel J L Baken, Ming Tian, Frederick W Alt, Bali Pulendran, Michael S Seaman, Max Crispin, Marit J van Gils, David C Montefiori, Adrian B McDermott, François J Villinger, Richard A Koup, John P Moore, Per Johan Klasse, Gabriel Ozorowski, Facundo D Batista, Ian A Wilson, Andrew B Ward, Rogier W Sanders

Förderung

  • Gates Foundation
  • NIGMS NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Caniels, T. G., Medina-Ramìrez, M., Zhang, S., Kratochvil, S., Xian, Y., Koo, J. H., Derking, R., Samsel, J., van Schooten, J., Pecetta, S., Lamperti, E., Yuan, M., Carrasco, M. R., Del Moral Sánchez, I., Allen, J. D., Bouhuijs, J. H., Yasmeen, A., Ketas, T. J., Snitselaar, J. L., …, & Sanders, R. W. (2024). Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Science Immunology, 9(98). https://doi.org/10.1126/sciimmunol.adk9550

Vancouver

Caniels TG, Medina-Ramìrez M, Zhang S, Kratochvil S, Xian Y, Koo JH, et al. Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Science Immunology. 2024;9(98). doi:10.1126/sciimmunol.adk9550

BibTeX
@article{Caniels2024,
  author = {Caniels, Tom G and Medina-Ramìrez, Max and Zhang, Shiyu and Kratochvil, Sven and Xian, Yuejiao and Koo, Ja-Hyun and Derking, Ronald and Samsel, Jakob and van Schooten, Jelle and Pecetta, Simone and Lamperti, Edward and Yuan, Meng and Carrasco, María Ríos and Del Moral Sánchez, Iván and Allen, Joel D and Bouhuijs, Joey H and Yasmeen, Anila and Ketas, Thomas J and Snitselaar, Jonne L and Bijl, Tom P L and Martin, Isabel Cuella and Torres, Jonathan L and Cupo, Albert and Shirreff, Lisa and Rogers, Kenneth and Mason, Rosemarie D and Roederer, Mario and Greene, Kelli M and Gao, Hongmei and Silva, Catarina Mendes and Baken, Isabel J L and Tian, Ming and Alt, Frederick W and Pulendran, Bali and Seaman, Michael S and Crispin, Max and van Gils, Marit J and Montefiori, David C and McDermott, Adrian B and Villinger, François J and Koup, Richard A and Moore, John P and Klasse, Per Johan and Ozorowski, Gabriel and Batista, Facundo D and Wilson, Ian A and Ward, Andrew B and Sanders, Rogier W},
  title = {Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site},
  journal = {Science Immunology},
  year = {2024},
  volume = {9},
  number = {98},
  doi = {10.1126/sciimmunol.adk9550}
}
Kostenlos starten →